OptimizeRx Stock Scores Healthy Composite Rating

OptimizeRx (OPRX) saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96. Is OptimizeRx stock on your watchlist?


The new score indicates OptimizeRx is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.

Is OptimizeRx Stock In The Buy Zone?

OptimizeRx stock is currently extended beyond a proper buy zone after clearing the 64.08 entry in a consolidation.

Looking For The Best Stocks To Buy And Watch? Start Here


One weak spot is the health technology company’s 66 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it’s in the top 20% of all stocks.

OptimizeRx stock’s Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.

In Q2, the company posted 400% EPS growth. Sales growth increased by 55%, up from 48% in the prior report. That marks one quarter of accelerating revenue gains. The company’s next quarterly report is expected on or around Nov. 9.

OptimizeRx stock earns the No. 1 rank among its peers in the Computer Software-Medical industry group. Inovalon (INOV) and Veeva Systems (VEEV) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
todayuknews Governmental News Finance News

Source link

Back to top button
Native News Post